Our Science

Non-alcoholic steatohepatitis (NASH) is a type of NAFLD (nonalcoholic fatty liver disease), which is the condition with stored excess of fat in liver. NAFLD is characterized by steatosis of the liver, and NASH is a necro-inflammatory process whereby the liver cells become injured  under steatosis.


Prevalence rate of NAFLD in China is estimated at 15.0%, or 208.5 million NAFLD patients, in 2017, and is expected to increase as less exercise and other lifestyle changes in the PRC population increase the risk of obesity.


Although there is a huge patient pool and unmet medical needs, currently there are no approved NASH drugs in the world. We are develop in-house breakthrough therapies for NASH focusing on novel targets.

nba比分 傲人沈阳棋牌 国王vs快船全场回放 日本av女优超像林熙蕾 中国核电股票 欧美av女星最漂亮排 吉林11选5 天津11选5任选基 欢乐麻将怎么开3个人房 4399美女麻将单机版 黑龙江十一选五结果 独行侠队标志 全球股票指数stock 彩吧3d图谜第三版 郑州按摩小姐联系电话 浙江快乐彩 泷川花音白衣服喷奶